Highlights Cue Biopharma, Inc.

Equities

CUE

US22978P1066

Market Closed - Nasdaq Other stock markets 21:00:00 10/05/2024 BST			5-day change	1st Jan Change
1.74 ^USD	-9.14%		-18.31%	-34.09%

05-09	Cue Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-08	Transcript : Cue Biopharma, Inc., Q4 2023 Earnings Call, Apr 08, 2024

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cue Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Cue Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
North American Morning Briefing : Tech in Focus on -2-	03-25	DJ
Cue Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-03	CI
Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and Cue-102 in Wilms' Tumor 1 Positive Cancers at SITC 2023	11-03	CI
Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®?	26/09/23	CI
Cue Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	08/08/23	CI
Cue Biopharma, Inc. Presents Positive Data Update from Ongoing Phase 1 Trials of Cue-101 for Recurrent/Metastatichpv+ Head and Neck Squamous Cell Carcinoma At the 2023 American Society of Clinical Oncology Annual Meeting	25/05/23	CI
Cue Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	09/05/23	CI
Cue Biopharma Signs Strategic Collaboration, Option Deal With Ono Pharmaceutical for CUE-401; Shares Decline	22/02/23	MT
Cue Biopharma, Inc. Enters into A Strategic Collaboration and Option Agreement with Ono Pharmaceutical for Cue-401	22/02/23	CI
Cue Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
Cue Biopharma, Inc. Presents New Positive Data from Ongoing Phase 1 Trial of Cue-101 in Combination with Keytruda for Recurrent/Metastatic Hpv+ Head and Neck Cancer At the Society for Immunotherapy of Cancer’s 37th Annual Meeting	10/11/22	CI
Cue Biopharma Grants FDA Fast Track Designation for CUE-101 for the Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma	04/10/22	CI
Cue Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	04/08/22	CI
Cue Biopharma Says FDA Approves Investigational New Drug Application for Early Trial of Cancer Treatment CUE-102	11/05/22	MT
U.S. Food and Drug Administration Accepts Cue Biopharma, Inc Investigational New Drug Application	11/05/22	CI
Cue Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	10/05/22	CI
Cue Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	16/03/22	CI
Correction: Cue Biopharma Says it has Reached a Key Milestone in LG Chem Life Sciences Collaboration on Cancer Drug Candidate	05/01/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Cue Biopharma, Inc.

Equities

CUE

US22978P1066

Highlights

Filters